ASCO 2023 | The role of EV and pembrolizumab in the urothelial carcinoma treatment landscape

Shilpa Gupta, MD, from the Cleveland Clinic, discusses the role of enfortumab vedotin (EV) and pembrolizumab treatment strategy in the urothelial carcinoma landscape. In the US, this option is available for cisplatin-ineligible patients, offering an additional choice alongside gemcitabine carboplatin with maintenance. While the approval of EV and pembrolizumab in urothelial carcinoma is established in the US, regulatory approvals in Europe, the UK, and Canada may await overall-survival (OS) signals. The treatment landscape is enriched with multiple options, enabling physicians to tailor treatments based on patient comorbidities and other factors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.